Shots:

• Ironwood to receive three non-contingent payment of $35M b/w 2021 & 2024- ~$90M as a milestone with royalties on sales of Linzess in China mainland- China Hong Kong and China Macau. AstraZeneca to get full rights to develop- manufacture & commercialize Linzess in China
• In Oct’2012- the companies collaborated to co-develop and co-commercialize Linzess and were jointly responsible for strategic oversight of the development and commercialization of Linzess in China while AstraZeneca had primary responsibility for local operational execution
• Linzess is a guanylate cyclase-C (GC-C) agonist- binds to it leading to an increased intestinal fluid secretion and accelerated transit with a decrease in the activity of pain-sensing nerves in the intestine and has received NMPA’s approval for irritable bowel syndrome with constipation (IBS-C) in Jan’2019 with its expected launch in 2019

Click here to­ read full press release/ article

Ref: AstraZeneca | Image: AstraZeneca